Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Kelly, W. K.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Armstrong, A. J.; Pook, D. W.; Kim, M.; Dorff, T.; Fischer, S.; Lin, Y. C.; Horvath, L. G.; Sumey, C.; Yang, Z.; Jurida, G.; Connarn, J.; Penny, H.; Stieglmaier, J.; Appleman, L. J. |
| Abstract Title: | Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | ESMO Asia Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | S1576 |
| Language: | English |
| ACCESSION: | WOS:001122475400264 |
| DOI: | 10.1016/j.annonc.2023.10.390 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 264P -- Source: Wos |
